In a placebo-controlled , double-blind , parallel-group trial , we investigated 34 postmenopausal women ( 17 in the placebo group and 17 in the medroxyprogesterone acetate [ MPA ] group ) whose SDB had been treated with nasal CPAP for 6 months to 8 years prior to study entry .